Genistein, an isoflavone present in soy at high concentrations and being considered the primary antitumor constituent in soy, has been known to be a natural anti-cancer agent in in vitro studies and experimental animal models. The present study was aimed to investigate to the putative chemopreventive effect of genistein on oral carcinogenesis in hamster cheek pouch at the post-initiation stage, as well as its effect on angiogenesis during this process. DMBA solution (0.5% in mineral oil) was applied topically to the left cheek pouch of male Syrian golden hamsters 3 times a week for 6 weeks. Two days after the last treatment of DMBA, genistein suspended in distilled water (10mg/kg /d), or same volume of distilled water were administered into the animals by gavage daily for 12 weeks. The genistein treatment decreased the visible oral tumor incidence to 40.7% (11/27) from 53.6% (15/28) of the positive control, but the difference was not statistically significant (P = 0.34). And no significant difference in the average number of tumors/tumor-bearing hamster, the average tumor volume or latency was observed between the control and genistein treated group. Vascular density in OSCC of the genistein treated group and that of the control group was similar and there was no significant difference. Importantly, 3 animals in the genistein treated group produced poorly-differenciated fibrosarcomas in the DMBA-painted cheek pouches. The exact mechanism behind this needs further investigation. In conclusion, no inhibitory effect of genistein on chemically induced post-initiation stage of oral carcinogenesis was observed in the present study. On the contrary, genistein appeared to promote oral submucosa stroma tumorigenesis in concert with DMBA. So caution should be warranted for people with predisposition to oral cancer.
Introduction
Oral squamous cell carcinoma (OSCC) is the most common of the head and neck cancers and has a poor prognosis. Multiple primary tumors are a known phenomenon in head and neck cancer (1) . Furthermore, local-regional recurrence is a common and challenging oncological problem in patients affected by this disease (2) . It has been proposed that carcinomas would arise from multifocal areas of precancerous change involved in the process of field cancerization (3) (4) (5) (6) . Thus the possibility of addressing the issue of precancerous tissue behavior would be contributory. Preventing or treating oral premalignant lesions with natural or synthetic chemical agents is now the most promising approach to prevent oral cancer.
The low incidence of breast cancer in Asian has been attributed, in part, to the high intake of soy products (7) (8) (9) . Experiments in animal models suggest that soy consumption decreases tumor number, incidence, latency, multiplicity and metastasis (10, 11) . Soy contains several potential anticancer agents, including protease inhibitors, phytosteroids, saponins phytates and and high level of isoflavones (12, 13) .
Genistein, one of the most studied isoflavones, is considered as the principle compound responsible for soy's beneficial effects (14) . As a weak antiestrogen, genisein has been shown to have multiple biological activities such as inhibiting topoisomerase II activity (7, 15) and tyrosine kinase activity (8, 16) , inducing cancer cell death, stimulating apoptosis (17) (15) , and suppressing angiogenesis (18) . However, clinical and preclinical laboratory animal and in vitro studies, aimed at evaluating the association between soy intake and reduction of breast cancer, are conflicting.
Petrakis et al. (19) demonstrated that consumption of soy protein isolate had stimulatory effects on the breast tissue of premenopausal women. Clinton et al. reported that soy protein isolates containing increasing concentrations of genistein stimulate the growth of estrogen-dependent breast cancer cells in vivo in a dose-dependent manner (20) . They also reported that the glycoside genistin, like the aglycone genistein, can stimulate estrogen-dependent breast cancer cell growth in vivo.
Removal of genistin or genistein from the diet caused tumors to regress (21) . reported that, in an OSCC-bearing nude mice model, the tumor growth and metastatic behavior in the genistein treated group and the control group were similar and there were no significant differences, although a significantly lower vascular density was found (23) . Moreover, people who have been diagnosed with oral leukoplakia or other oral premalignant lesions often inquire whether soy products, including genistein, will protect from malignant transformation of their diseases. But right now there are even less report about the preventive effect of genistein on oral precancerous lesions.
The development of oral cancer is a multi-step process requiring initiation, promotion and progression. Application of 7,12-dimethylbenz[a]anthracene (DMBA) to the cheek pouch of the Syrian golden hamster produces SCC and premalignant lesions that are histologically similar to the lesions in human (24, 25) . After 6 week's DMBA treatment, mucosa lesions of the hamster cheek pouches are just at premalignant stage, which are similar with human cases with oral leukoplakia or heavy smokers. This post-initiation stage could be a good time to test the primary preventive effect of chemopreventive agents.
The purpose of the present study was to address two objectives. First, to investigate whether genistein, at a dosage relevant to the real-life consumption pattern, has inhibitory effect on the malignant conversion of oral precancerous lesions. Secondly, to test whether genistein has anti-angiogenic effect during this process of transformation. 
Materials and methods

Treatment of animals
Pathological and histopathological examinations
At the completion of the study, animals were killed by cervical dislocation. The 
Angiogenesis
To assess the angiogenesis of the squamous epithelium of the oral mucosa, tissue sections were immunostained with a rabbit anti-factor VIII antibody (1:500; DAKO Corporation, Carpinteria, CA). Briefly, sections were pretreated with 0.25% trypsin for 10 min at 37°C, After washing, the samples were incubated in 10% normal swine serum for 20 min, followed by rabbit antihuman von Willebrand factor (1:500), biotinylated swine antirabbit antibody (1:400) for 30 min, and streptavidin biotin complex/horseradish peroxidase for 30 min. All of the sera and avidin biotin reagents were obtained from Dako. In non-lesioned area and preinvasive lesions including hyperplasia, dysplasia and benign papillomas, the blood vessels in submucosa were counted. In carcinoma, peritumoral vessels were counted. Highly vascularized areas were identified by scanning sections at low power (x40 and x100). After six areas of highest neovascularization were identified, the number of vessel count was performed on a x200 field (x20 objective and x10 ocular), and the average counts of the six fields were determined. Vessel lumens were not necessary for a structure to be defined as a vessel.
Statistical analysis
The tumor incidence of different groups was compared by the chisquare test and 
Results
Effect of genistein on DMBA-induced oral carcinogenesis in hamster
At week 6, all DMBA-treated animals had a visibly roughened granular surface on the mucosa with varying degrees of erythema and occasional white plaque-like lesion.
Cheek pouches of animals from the mineral oil-treated and untreated groups revealed no obvious changes.
In hamsters treated with DMBA followed by genistein, tumors took a little bit longer For both parameters, the differences did not reach any statistical significance (Table   Ⅰ) .
Histologically, in accordance with previous reports, the left buccal pouches of DMBA-treated animals presented areas of leukoplakia with hyperplasia or dysplasia Table Ⅱ) .
The number of dysplastic lesion and papilloma per animal was not different between the positive group and the genistein treated group (Table Ⅲ) . No oral lesions were found in animals from the mineral oil-treated and untreated groups.
Angiogenesis
In DMBA-induced oral lesions, the neovascularies primarily concentrated in the stromal areas and spread along stromal ridges on the periphery of epithelial lesions Table Ⅳ ) .
Compared with Group A, genistein treatment did not lead to any significant decrease of vessel density in OSCC (Figure 2e ).
In the fibrosarcoma tissue sections of the genistein treated group, neovascularies scattered in the tumor areas, with vascular vessels lack of complete lumen and regular formation. The vascular density is much lower than that in the OSCC tissues ( Figure   2f ).
Discussion
The present study was aimed at investigating whether genistein, administered since post-initiation stage and at a dosage relevant to the real-life consumption pattern, can influence chemically-induced oral carcinogenesis in male hamsters as well as its possible effect on angiogenesis during this process. In order to find out whether the eastern eating habit of soy foods has any protective effect against oral cancer, we tried to make the dosage we used relate to the real-life consumption patterns. However, we did not see any statistical differences in tumor incidence, tumor volume, tumor multiplicity and tumor latency, although genistein treatment decreased the tumor bearing animals to 11/27 from 15/28. Despite the anti-cancer effect of genistein on OSCC was shown in some in vitro studies (22, 27) , it is noted that the concentration required to obtain this effect was higher than the plasma level of genistein in people In addition, with view to the timing of exposure determining the metabolism, bioavailability and biological action of genistein, dosing genistein after exposure to DMBA may not be able to maximize the chemopreventive effect, since it takes a few days to weeks for genistein to reach a pharmacologically steady state in vivo. So we are carrying out a series of studies right now in our laboratory, attempting to find out the effects of genistein, in varied concentrations, on oral carcinogenesis when dosed with before exposure to carcinogens or at the same time with carcinogens exposure.
We hope to find out the dose-response relationship and the timing of the genistein treatment with oral carcinogenesis.
With regard to the in vivo studies, Myoung H et al did not find any inhibitory effect of genistein on the transplanted human OSCC all through the study period, although a decrease of microvessel density was observed (23) . In the present study, genistein treatment did not lead to statistically significant decrease of vessel density in OSCC or lesions with dysplasia. In Myoung's study, the rapidly growing transplantable mouse tumor model was employed, which are usually grown as a solid, localized tumor in the subcutaneous space. This kind of tumor models will contain an extremely high proportion of newly formed immature vessels, and it is just such vessels which appear to be especially vulnerable to the effects of most anti-angiogenic drugs (32).
Consequently, this approach almost certainly exaggerates the anti-angiogenesis responses. Secondly, the response of a tumor mass growing ectopically may be abnormal compared with the same tumor growing in a physiologically relevant site (33) . Thirdly, we investigated the effects of genistein through oral intake instead of s.c. injection as described in Myoung's study, the former is just the way human take genistein. Thus we believe the results of the present study would provide a more faithful picture of what will occur later in the clinic, although there are still much difference between animal tumors and human tumors.
We also showed in the present study that genistein treatment caused occurrence of poorly-differenciated fibrosarcomas in three of the DMBA-treated hamsters. To the best of our knowledge, this was the first time that fibrosarcoma was induced in the hamster cheek pouches by DMBA treatment conjuncted with genistein. The Syrian hamster buccal pouch is thought of as an excellent model for studying oral carcinogenesis which, under the induction of 7,12-dimethylbenz[a]anthracene, consistently produces squamous cell carcinomas as well as the precancerous leukoplakias that precede them. However, in the present study, we found that after 6 week's DMBA induction and subsequently 12 week's genistein intervention, the cheek pouches of 3 out of 27 hamsters produced fibrosarcoma, another 8 hamsters produced OSCC. It was conceivable that these fibrosarcomas was resulted，at lest partly, from the effect of genistein. The precise reasons for this are unclear, we speculated that it may be a result of estrogenic activity of genistein (34) . Bundles of studies have shown that estrogen had a biological role in oral mucosa, with estrogen receptor-beta the predominant estrogen receptor subtype (35, 36) . Another study also
showed that the gingival stroma of rats is a target organ of estrogen. In their study, the author noticed that estradiol induces alterations of gingival lamina propria, such as increase in activity of fibroblasts, number of eosinophils and intercellular substance, the promotion effect of estrogen on the growth of stoma was strongly suggested (37).
Therefore, it is possible that the hormonal activity of genistein acted in concert with carcinogen DMBA to give rise to the carcinogenic effects.
Besides its estrogen-like activity, genistein was also reported to be genotoxic. Metzler M et al reported that genistein was clastogenic in cultured mammalian cells and lead to gene mutation; it was proved to be strong inducers of DNA strand breaks and micronuclei containing acentric fragments (38, 39) . On the other hand, it should be noted that, for most people, soy is a healthy food. As one of our previous studies (haven't published overseas yet) showed, genistein treatment only induced no tumor masses or leukoplakia-like lesions on hamster cheek pouches. Histopothological examination also showed all cheek pouches of these hamsters were normal. In this study, no carcinogenic activity was observed with genistein per se. Different experimental protocol and marked differences in concentration and quali-quantitative composition of the soy products used may lead to such contrary results. Further investigations are needed to clarify this confusion. After all, isoflavones are more than phytoestrogens, they also possess nonhormonal properties; for example, they exert antioxidant effects under some experimental conditions (40 ,41) and influence the activity of enzymes involved in the metabolism of estrogen, and that regulate cell growth and differentiation (42, 43) .
It has been suggested that women with estrogen-dependent breast cancer or a predisposition to it may want to reduce their consumption of soy products with high isoflavone content (44). According to the results of our study, not only for women with breast cancer but also for people with oral leukoplakia or those with prior exposure to carcinogens, such as heavey smokers, there is need for additional consideration into the possibility of enhancing or promoting tumor growth by consumption of isoflavone containing products.
In conclusion, our research did not find genistein, administered since post-initiation stage and at a dosage relevant to the real-life consumption pattern, have any preventive effect on DMBA-induced oral carcinogenesis in hamster cheek pouch.
Moreover, it showed that genistein might modify the histomorphological characteristic of the occurring tumors which expressed a rather poor differentiation.
Under the joint action of genistein, not only the squamous epithelium but also the submucosa stroma may undergo malignant transformation during the DMBA-induced carcinogenesis. Though this novel finding needs validation and the mechanism behind this needs further investigation, caution is necessary for people with oral leukoplakia or former and current smokers consuming dietary genistein. MVD （microvessel density） = vessel count/ high powered field, magnification is×200. The number of vWF-positive blood vessels was counted as described in "Materials and Methods". The MVD in fibrosarcomas of the gensitein treated group was significantly lowed than that in OSCC both of the genistein treated group (group A) and the positive control group (group B) (p<0.01). But no decrease of MVD was observed between the genistein treated group (group A) and the positive control (group B) (by one way ANOVA test). 
